Directors' Dealings at STRATEC SE

The members of the Board of Management and the Supervisory Board of STRATEC SE, as well as persons closely associated with them, must notify STRATEC SE and the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) of transactions in financial instruments of STRATEC SE or derivatives of these financial instruments.

All transactions that are subject to disclosure requirements are listed, together with the information required by law (before July 3, 2016 pursuant to § 15a of the German Securities Trading Act (Wertpapierhandelsgesetz, WpHG); from July 3, 2016 pursuant to Art. 19 of the Market Abuse Regulation).

Directors Dealings

2026

2025

2024

2023

2022

no content available.

Datum	Titel
03/17/2023	STRATEC SE: Marcus Wolfinger, buy
03/15/2023	STRATEC SE: Marcus Wolfinger, buy
03/13/2023	STRATEC SE: Marcus Wolfinger, buy
03/10/2023	STRATEC SE: Prof. Dr. Georg Heni, buy
03/10/2023	STRATEC SE: Marcus Wolfinger, buy

Datum	Titel
11/16/2022	STRATEC SE: Dr. Claus Vielsack, Sale of 2,000 STRATEC shares previously acquired by exercising stock options in STRATEC SE. These stock options were granted to the individual in question from the stock option plan in 2018 as a variable compensation component.
11/16/2022	STRATEC SE: Dr. Robert Siegle, Sale of 2,000 STRATEC shares previously acquired by exercising stock options in STRATEC SE. These stock options were granted to the individual in question from the stock option plan in 2018 as a variable compensation component.
11/16/2022	STRATEC SE: Marcus Wolfinger, Sale of 3,500 STRATEC shares previously acquired by exercising stock options in STRATEC SE. These stock options were granted to the individual in question from the stock option plan in 2018 as a variable compensation component.
11/16/2022	STRATEC SE: Dr. Claus Vielsack, Purchase of 2,500 STRATEC shares due to exercising of stock options in STRATEC SE. These stock options were granted to the individual in question from the stock option plan in 2018 as a variable compensation component.
11/16/2022	STRATEC SE: Dr. Robert Siegle, Purchase of 2,500 STRATEC shares due to exercising of stock options in STRATEC SE. These stock options were granted to the individual in question from the stock option plan in 2018 as a variable compensation component.
11/16/2022	STRATEC SE: Marcus Wolfinger, Purchase of 5,000 STRATEC shares due to exercising of stock options in STRATEC SE. These stock options were granted to the individual in question from the stock option plan in 2018 as a variable compensation component.
01/26/2022	STRATEC SE: Dr. Claus Vielsack, Acceptance of 2,500 stock options, each entitling the Executive Board member to purchase one STRATEC SE share through the participation in the SOP 2018 (variable compensation component). Exercisability of stock options depends in particular on achievement of the performance target and expiry of the four-year waiting period. Details about the SOP 2018 can be found in the invitation to the 2018 Annual General Meeting published in the Federal Gazette on April 19, 2018.
01/26/2022	STRATEC SE: Dr. Robert Siegle, Acceptance of 2,500 stock options, each entitling the Executive Board member to purchase one STRATEC SE share through the participation in the SOP 2018 (variable compensation component). Exercisability of stock options depends in particular on achievement of the performance target and expiry of the four-year waiting period. Details about the SOP 2018 can be found in the invitation to the 2018 Annual General Meeting published in the Federal Gazette on April 19, 2018.
01/26/2022	STRATEC SE: Marcus Wolfinger, Acceptance of 5,000 stock options, each entitling the Executive Board member to purchase one STRATEC SE share through the participation in the SOP 2018 (variable compensation component). Exercisability of stock options depends in particular on achievement of the performance target and expiry of the four-year waiting period. Details about the SOP 2018 can be found in the invitation to the 2018 Annual General Meeting published in the Federal Gazette on April 19, 2018.

Datum	Titel
03/17/2023	STRATEC SE: Marcus Wolfinger, buy
03/15/2023	STRATEC SE: Marcus Wolfinger, buy
03/13/2023	STRATEC SE: Marcus Wolfinger, buy
03/10/2023	STRATEC SE: Prof. Dr. Georg Heni, buy
03/10/2023	STRATEC SE: Marcus Wolfinger, buy

Datum	Titel
11/16/2022	STRATEC SE: Dr. Claus Vielsack, Sale of 2,000 STRATEC shares previously acquired by exercising stock options in STRATEC SE. These stock options were granted to the individual in question from the stock option plan in 2018 as a variable compensation component.
11/16/2022	STRATEC SE: Dr. Robert Siegle, Sale of 2,000 STRATEC shares previously acquired by exercising stock options in STRATEC SE. These stock options were granted to the individual in question from the stock option plan in 2018 as a variable compensation component.
11/16/2022	STRATEC SE: Marcus Wolfinger, Sale of 3,500 STRATEC shares previously acquired by exercising stock options in STRATEC SE. These stock options were granted to the individual in question from the stock option plan in 2018 as a variable compensation component.
11/16/2022	STRATEC SE: Dr. Claus Vielsack, Purchase of 2,500 STRATEC shares due to exercising of stock options in STRATEC SE. These stock options were granted to the individual in question from the stock option plan in 2018 as a variable compensation component.
11/16/2022	STRATEC SE: Dr. Robert Siegle, Purchase of 2,500 STRATEC shares due to exercising of stock options in STRATEC SE. These stock options were granted to the individual in question from the stock option plan in 2018 as a variable compensation component.
11/16/2022	STRATEC SE: Marcus Wolfinger, Purchase of 5,000 STRATEC shares due to exercising of stock options in STRATEC SE. These stock options were granted to the individual in question from the stock option plan in 2018 as a variable compensation component.
01/26/2022	STRATEC SE: Dr. Claus Vielsack, Acceptance of 2,500 stock options, each entitling the Executive Board member to purchase one STRATEC SE share through the participation in the SOP 2018 (variable compensation component). Exercisability of stock options depends in particular on achievement of the performance target and expiry of the four-year waiting period. Details about the SOP 2018 can be found in the invitation to the 2018 Annual General Meeting published in the Federal Gazette on April 19, 2018.
01/26/2022	STRATEC SE: Dr. Robert Siegle, Acceptance of 2,500 stock options, each entitling the Executive Board member to purchase one STRATEC SE share through the participation in the SOP 2018 (variable compensation component). Exercisability of stock options depends in particular on achievement of the performance target and expiry of the four-year waiting period. Details about the SOP 2018 can be found in the invitation to the 2018 Annual General Meeting published in the Federal Gazette on April 19, 2018.
01/26/2022	STRATEC SE: Marcus Wolfinger, Acceptance of 5,000 stock options, each entitling the Executive Board member to purchase one STRATEC SE share through the participation in the SOP 2018 (variable compensation component). Exercisability of stock options depends in particular on achievement of the performance target and expiry of the four-year waiting period. Details about the SOP 2018 can be found in the invitation to the 2018 Annual General Meeting published in the Federal Gazette on April 19, 2018.

DIRECTORS'
DEALINGS

DIRECTORS'
DEALINGS